There are a number of things I particularly like about the IONIC...

There are a number of things I particularly like about the IONIC trial:

• IONIC is a study involving both NOX and Bristol-Myers Squibb
• Cohort 1 will have recently failed Opdivo – any improvement should be quickly apparent and will be due to Veyonda
• Cohort 2 will be unsuitable for Opdivo – any response will prove that Veyonda can restore the immune function in all tumours
• Veyonda will be used at higher dosages than in earlier trials
• As Veyonda plus Opdivo could threaten the position of Keytruda, I imagine that Merck will closely watch developments
• In an ideal world, BMS and Merck would get into a bidding war.